newsfilter
← Latest News
GlobeNewswire·

Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models

HIGHLIGHTS Amplia's lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical models of pancreatic